Aurora Doubles German Cannabis Output, Giving Investors More to Weigh in Curaleaf Takeover

Aurora’s expanded EU-GMP facility strengthens its European manufacturing footprint just days after Curaleaf raised its hostile acquisition offer to $5 per share.

Aurora Cannabis (NASDAQ: ACB) has completed a multimillion-dollar expansion of its medical cannabis manufacturing facility in Leuna, Germany, positioning the Canadian producer to more than double expected annual flower output as it faces an increasingly aggressive takeover attempt from Curaleaf Holdings.

The facility, renamed Aurora Horizon, has received expanded EU-GMP authorization for newly constructed production areas from the State Office for Social Affairs, Youth and Health of Saxony-Anhalt, according to an October 8 filing with the U.S. Securities and Exchange Commission.

The investment increases Aurora’s domestic production capacity in Germany, where the company is one of only three licensed local cannabis producers.

It also comes at a consequential moment for Aurora shareholders. On October 5, Curaleaf increased its hostile takeover offer by 25%, raising its implied consideration to $5 per Aurora share.

A larger European manufacturing footprint

Aurora said the Leuna expansion incorporates cultivation and post-harvest practices developed at its Canadian operations, including improvements to lighting, irrigation, harvesting and processing.

The facility has also adopted proprietary genetics developed at Aurora Coast, the company’s research and development operation in British Columbia.

“The completion of our Leuna facility transformation is an important milestone for Aurora and reinforces our commitment to serving patients in our fastest-growing markets, including Germany, where we are proud to be a domestic manufacturer,” said Alex Miller, Aurora’s executive vice president of operations and supply chain.

The company expects annual flower output at the expanded facility to more than double, although it did not disclose the site’s previous production volume, its new annual capacity in kilograms, or the precise investment amount.

Aurora also expects the expansion to improve operational efficiency and supply chain resilience as it serves Germany and other European medical cannabis markets.

Local reporting provides additional details. According to Leuna Echo, the project involved an investment in the mid-single-digit millions of euros and increased the facility’s workforce by ten employees to 55.

Expansion during a hostile takeover

The announcement comes as Aurora’s board evaluates Curaleaf’s revised acquisition proposal.

Under the amended offer filed October 6, Aurora shareholders would receive $1 in cash and 0.4013 Curaleaf subordinate voting shares for each Aurora share tendered.

The offer carries an implied value of $5 per share based on Curaleaf’s October 2 closing price, with a maximum consideration cap of $6 per Aurora share under the offer’s adjustment mechanism.

Aurora’s board has not endorsed the revised proposal.

In an October 6 statement, Executive Chairman and CEO Miguel Martin urged shareholders to wait for the company’s formal recommendation.

“The filing of a revised Hostile Bid is simply the next step in the process, not a deadline to make a decision,” Martin said.

Aurora shareholders have until at least December 4 to consider the offer.

The German expansion adds another operating development for investors to consider as they evaluate Aurora’s standalone prospects against the potential benefits of combining with Curaleaf.

What the investment means for Aurora’s valuation

Aurora’s European operations have been central to the strategic rationale behind Curaleaf’s acquisition attempt.

Expanding domestic manufacturing capacity in Germany potentially strengthens Aurora’s ability to supply one of Europe’s largest medical cannabis markets without relying exclusively on imported products.

It could also improve production economics through greater utilization, consistent genetics, and more efficient post-harvest processing.

However, the October 8 announcement does not quantify the additional revenue, margins, or cash flow Aurora expects from the investment.

“The completion of our Leuna facility transformation is an important milestone for Aurora and reinforces our commitment to serving patients in our fastest-growing markets, including Germany, where we are proud to be a domestic manufacturer,” said Alex Miller, EVP, Operations and Supply Chain at Aurora in the company’s SEC filing this week. “Now known as Aurora Horizon, the EU GMP-licensed facility strengthens our ability to serve patients in Germany, while advancing our broader European growth strategy.”

Those figures will ultimately determine how much financial value the additional capacity creates.

For shareholders weighing Curaleaf’s revised offer, the distinction matters. Aurora has completed a capital investment that expands its productive assets, but it has yet to demonstrate those assets’ contribution to future earnings.

The facility expansion does not establish that Curaleaf’s offer undervalues Aurora. It does, however, provide another development against which shareholders can assess the company’s standalone growth strategy.

As Aurora expands its European production footprint and Curaleaf presses ahead with its takeover bid, questions of asset valuation, international growth and consolidation remain central to the cannabis industry’s future. These issues will be part of the conversation at IgniteIt’s Capital & Policy Summit in Washington, D.C., on November 18, where industry executives, investors and policymakers will examine the financial and regulatory forces shaping the next phase of cannabis investment.